Symbols / TCRX Stock $1.25 -1.57% TScan Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
TCRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Fundamentals
Scroll to Statements
Market Cap 75.13M Enterprise Value 12.86M Income -129.77M Sales 10.32M Book/sh 2.16 Cash/sh 2.68
Dividend Yield — Payout 0.00% Employees 142 IPO — P/E — Forward P/E -1.63
PEG — P/S 7.28 P/B 0.58 P/C — EV/EBITDA -0.10 EV/Sales 1.25
Quick Ratio 8.15 Current Ratio 8.41 Debt/Eq 76.46 LT Debt/Eq — EPS (ttm) -1.00 EPS next Y -0.77
EPS Growth — Revenue Growth 286.00% Earnings 2026-03-04 ROA -27.88% ROE -71.28% ROIC —
Gross Margin 0.00% Oper. Margin -8.52% Profit Margin 0.00% Shs Outstand 55.82M Shs Float 47.79M Short Float 4.03%
Short Ratio 3.16 Short Interest — 52W High 2.57 52W Low 0.88 Beta 1.01 Avg Volume 783.54K
Volume 740.62K Target Price $6.00 Recom Strong_buy Prev Close $1.27 Price $1.25 Change -1.57%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.25
Latest analyst target
3. DCF / Fair value
$-31.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.25
Low
$5.00
High
$7.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-05 main Wedbush Outperform → Outperform $5
2025-11-13 main HC Wainwright & Co. Buy → Buy $7
2025-11-04 down BTIG Buy → Neutral —
2025-11-04 main Needham Buy → Buy $6
2025-05-07 main HC Wainwright & Co. Buy → Buy $10
2025-04-08 reit Needham Buy → Buy $9
2025-03-07 main Barclays Overweight → Overweight $3
2025-03-06 reit HC Wainwright & Co. Buy → Buy $15
2025-03-05 main Needham Buy → Buy $9
2024-12-11 reit HC Wainwright & Co. Buy → Buy $15
2024-12-11 reit Needham Buy → Buy $11
2024-11-15 reit HC Wainwright & Co. Buy → Buy $15
2024-11-12 reit Needham Buy → Buy $11
2024-11-06 reit Needham Buy → Buy $11
2024-08-13 reit Wedbush Outperform → Outperform $10
2024-08-13 reit HC Wainwright & Co. Buy → Buy $15
2024-08-12 reit Needham Buy → Buy $11
2024-06-04 reit HC Wainwright & Co. Buy → Buy $15
2024-05-16 init BTIG — → Buy $12
2024-05-14 reit HC Wainwright & Co. Buy → Buy $15
News
RSS: Latest TCRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-23 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 161,801 $0.90 $145,526
2025-05-20 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 2,588,794 $1.20 $3,106,553
2024-12-13 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 131,800 $2.90 $385,769
2024-11-15 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 947 $4.34 $4,114
2024-09-23 KLENCKE BARBARA M.D. Director — 5,000 $5.29 $26,450
2024-08-26 KLENCKE BARBARA M.D. Director — 10,000 $5.53 $56,100
2024-08-23 ZDRAVESKI ZORAN Officer — 164,686 $5.78 $952,116
2024-08-23 ZDRAVESKI ZORAN Officer — 157,186 $1.81 $531,520
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
10.32
+266.65%
2.82
-86.62%
21.05
+55.52%
13.54
Operating Revenue
10.32
+266.65%
2.82
-86.62%
21.05
+55.52%
13.54
Operating Expense
146.14
+6.18%
137.64
+20.20%
114.51
+42.83%
80.17
Research And Development
114.15
+6.33%
107.35
+21.78%
88.15
+47.37%
59.82
Selling General And Administration
31.33
+6.00%
29.56
+15.95%
25.49
+25.26%
20.35
General And Administrative Expense
31.33
+6.00%
29.56
+15.95%
25.49
+25.26%
20.35
Salaries And Wages
17.16
+9.96%
15.60
+36.90%
11.40
-2.21%
11.65
Other Gand A
14.18
+1.57%
13.96
-0.99%
14.10
+62.05%
8.70
Total Expenses
146.14
+6.18%
137.64
+20.20%
114.51
+42.83%
80.17
Operating Income
-135.81
-0.74%
-134.82
-44.26%
-93.46
-40.25%
-66.64
Total Operating Income As Reported
-135.81
-0.74%
-134.82
-44.26%
-93.46
-40.25%
-66.64
EBITDA
-124.13
-3.67%
-119.74
-49.49%
-80.10
-33.70%
-59.91
Normalized EBITDA
-124.13
-4.62%
-118.65
-48.13%
-80.10
-33.70%
-59.91
Reconciled Depreciation
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
EBIT
-127.00
-2.54%
-123.85
-44.92%
-85.46
-31.38%
-65.05
Total Unusual Items
0.00
+100.00%
-1.09
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-1.09
0.00
—
Special Income Charges
0.00
+100.00%
-1.09
0.00
—
Other Special Charges
—
1.09
—
—
Net Income
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Pretax Income
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Non Operating Interest Income Expense
6.05
-28.11%
8.41
+98.40%
4.24
+921.69%
0.41
Interest Expense Non Operating
2.77
-24.20%
3.65
-2.82%
3.76
+219.64%
1.18
Net Interest Income
6.05
-28.11%
8.41
+98.40%
4.24
+921.69%
0.41
Interest Expense
2.77
-24.20%
3.65
-2.82%
3.76
+219.64%
1.18
Interest Income Non Operating
8.82
-26.93%
12.06
+50.83%
8.00
+402.77%
1.59
Interest Income
8.82
-26.93%
12.06
+50.83%
8.00
+402.77%
1.59
Other Income Expense
—
-1.09
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income From Continuing Operation Net Minority Interest
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income From Continuing And Discontinued Operation
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Net Income Continuous Operations
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Normalized Income
-129.77
-2.66%
-126.41
-41.69%
-89.22
-34.73%
-66.22
Net Income Common Stockholders
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Diluted EPS
-1.00
+12.28%
-1.14
+16.18%
-1.36
+50.55%
-2.75
Basic EPS
-1.00
+12.28%
-1.14
+16.18%
-1.36
+50.55%
-2.75
Basic Average Shares
129.78
+15.88%
111.99
+70.72%
65.60
+172.78%
24.05
Diluted Average Shares
129.78
+15.88%
111.99
+70.72%
65.60
+172.78%
24.05
Diluted NI Availto Com Stockholders
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Depreciation Amortization Depletion Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Depreciation And Amortization In Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Depreciation Income Statement
0.66
-9.89%
0.73
-15.55%
0.86
—
Total Other Finance Cost
—
—
—
—
Line Item Trend 2023-12-31 2021-12-31
Total Assets
272.15
—
Current Assets
194.24
—
Cash Cash Equivalents And Short Term Investments
192.04
—
Cash And Cash Equivalents
133.36
—
Other Short Term Investments
58.69
—
Prepaid Assets
—
4.25
Other Current Assets
2.19
—
Total Non Current Assets
77.91
—
Net PPE
71.23
—
Gross PPE
85.83
—
Accumulated Depreciation
-14.60
—
Properties
0.00
—
Machinery Furniture Equipment
2.98
—
Construction In Progress
0.55
—
Other Properties
79.14
—
Leases
3.16
—
Non Current Prepaid Assets
—
0.17
Other Non Current Assets
6.68
—
Total Liabilities Net Minority Interest
121.28
—
Current Liabilities
29.82
—
Payables And Accrued Expenses
7.19
—
Payables
2.37
—
Accounts Payable
2.37
—
Current Accrued Expenses
4.81
—
Pensionand Other Post Retirement Benefit Plans Current
5.48
—
Current Debt And Capital Lease Obligation
6.59
—
Current Debt
3.35
—
Other Current Borrowings
3.35
—
Current Capital Lease Obligation
3.25
—
Current Deferred Liabilities
10.14
—
Current Deferred Revenue
10.14
—
Other Current Liabilities
0.42
—
Total Non Current Liabilities Net Minority Interest
91.46
—
Long Term Debt And Capital Lease Obligation
85.84
—
Long Term Debt
26.70
—
Long Term Capital Lease Obligation
59.14
—
Non Current Deferred Liabilities
5.62
—
Non Current Deferred Revenue
5.62
—
Other Non Current Liabilities
—
0.10
Stockholders Equity
150.87
—
Common Stock Equity
150.87
—
Capital Stock
0.01
—
Common Stock
0.01
—
Preferred Stock
0.00
—
Share Issued
47.83
—
Ordinary Shares Number
47.83
—
Treasury Shares Number
0.00
-100.00%
0.12
Additional Paid In Capital
398.46
—
Retained Earnings
-247.60
—
Gains Losses Not Affecting Retained Earnings
0.00
—
Other Equity Adjustments
—
—
Total Equity Gross Minority Interest
150.87
—
Total Capitalization
177.57
—
Working Capital
164.42
—
Invested Capital
180.91
—
Total Debt
92.43
—
Capital Lease Obligations
62.39
—
Net Tangible Assets
150.87
—
Tangible Book Value
150.87
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-135.32
-22.10%
-110.82
-80.62%
-61.36
+7.74%
-66.50
Cash Flow From Continuing Operating Activities
-135.32
-22.10%
-110.82
-80.62%
-61.36
+7.74%
-66.50
Net Income From Continuing Operations
-129.77
-1.78%
-127.50
-42.91%
-89.22
-34.73%
-66.22
Depreciation Amortization Depletion
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Depreciation
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Depreciation And Amortization
2.87
-30.23%
4.11
-23.37%
5.36
+4.36%
5.14
Other Non Cash Items
0.46
-40.23%
0.77
+2.11%
0.76
+191.15%
0.26
Stock Based Compensation
11.71
+22.59%
9.55
+83.35%
5.21
+14.44%
4.55
Operating Gains Losses
—
1.09
—
—
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-18.18
-459.68%
5.05
-71.29%
17.61
+272.10%
-10.23
Change In Prepaid Assets
-0.53
+2.42%
-0.54
-154.62%
0.98
+340.24%
-0.41
Change In Payables And Accrued Expense
-10.24
-256.86%
6.53
+71.69%
3.80
+201.67%
1.26
Change In Accrued Expense
-7.23
-259.44%
4.53
+17.62%
3.85
+426.37%
0.73
Change In Payable
-3.01
-251.00%
1.99
+3934.62%
-0.05
-109.85%
0.53
Change In Account Payable
-3.01
-251.00%
1.99
+3934.62%
-0.05
-109.85%
0.53
Change In Other Working Capital
-7.42
-694.00%
-0.93
-107.29%
12.82
+215.70%
-11.08
Investing Cash Flow
109.37
+307.88%
-52.61
+13.41%
-60.76
-1338.08%
-4.22
Cash Flow From Continuing Investing Activities
109.37
+307.88%
-52.61
+13.41%
-60.76
-1338.08%
-4.22
Net PPE Purchase And Sale
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Purchase Of PPE
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Capital Expenditure
-4.41
-15.22%
-3.83
-21.58%
-3.15
+25.54%
-4.22
Net Investment Purchase And Sale
113.78
+333.21%
-48.79
+15.32%
-57.61
0.00
Purchase Of Investment
-87.47
+63.77%
-241.44
-211.09%
-77.61
0.00
Sale Of Investment
201.25
+4.46%
192.66
+863.29%
20.00
0.00
Financing Cash Flow
-0.34
-100.16%
208.76
+54.13%
135.44
+361.38%
29.36
Cash Flow From Continuing Financing Activities
-0.34
-100.16%
208.76
+54.13%
135.44
+361.38%
29.36
Net Issuance Payments Of Debt
0.00
-100.00%
15.31
0.00
-100.00%
29.35
Issuance Of Debt
0.00
-100.00%
32.46
0.00
-100.00%
29.35
Repayment Of Debt
0.00
+100.00%
-17.14
0.00
—
Long Term Debt Issuance
0.00
-100.00%
32.46
0.00
-100.00%
29.35
Long Term Debt Payments
0.00
+100.00%
-17.14
0.00
—
Net Long Term Debt Issuance
0.00
-100.00%
15.31
0.00
-100.00%
29.35
Net Common Stock Issuance
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Cash Dividends Paid
0.00
0.00
—
—
Proceeds From Stock Option Exercised
0.26
-99.84%
160.32
+72.33%
93.03
+69846.62%
0.13
Net Other Financing Charges
-0.40
—
—
-0.32
Changes In Cash
-26.28
-157.98%
45.33
+240.16%
13.33
+132.21%
-41.37
Beginning Cash Position
183.72
+32.76%
138.39
+10.66%
125.06
-24.86%
166.44
End Cash Position
157.44
-14.31%
183.72
+32.76%
138.39
+10.66%
125.06
Free Cash Flow
-139.73
-21.87%
-114.65
-77.74%
-64.50
+8.80%
-70.73
Interest Paid Supplemental Data
2.31
-19.92%
2.88
-4.03%
3.00
+354.85%
0.66
Amortization Of Securities
-2.41
+38.18%
-3.90
-263.53%
-1.07
0.00
Common Stock Issuance
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Interest Paid CFF
-0.20
0.00
—
—
Issuance Of Capital Stock
0.00
-100.00%
33.13
-21.89%
42.41
+21876.17%
0.19
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category